Prelude Therapeutics (PRLD) Net Equity Issued and Repurchased (2020 - 2021)

Prelude Therapeutics (PRLD) reported Net Equity Issued and Repurchased of $161.4 million for Q1 2021, up 439.88% on a YoY basis from $29.9 million in Q1 2020, and up 384242.86% sequentially from $42000.0 in Q2 2020.

Prelude Therapeutics (PRLD) Net Equity Issued and Repurchased (2020 - 2021) Analysis & Trends

Prelude Therapeutics (PRLD) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $161.4 million in Q1 2021.

  • For the quarter ending Q1 2021, Net Equity Issued and Repurchased rose 439.88% year-over-year to $161.4 million; the trailing twelve-month figure through Dec 2021 stood at $161.4 million (up 439.12% YoY), and the FY2021 full-year result was $161.4 million, up 223.98% from the prior year.
  • Net Equity Issued and Repurchased grew to $161.4 million in Q1 2021, from $42000.0 in the prior quarter.
  • In the past five years, Net Equity Issued and Repurchased ranged from a high of $161.4 million in Q1 2021 to a low of $42000.0 in Q2 2020.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Prelude Therapeutics 324.30 Mn 179.71 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2021 161.42 Mn
Mar 31, 2021 161.42 Mn
Jun 30, 2020 42,000.00
Jun 30, 2020 42,000.00
Mar 31, 2020 29.90 Mn
Mar 31, 2020 29.90 Mn